Overview

The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor

Status:
Completed
Trial end date:
2019-03-07
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, pharmacokinetics, food effect, and preliminary antitumor activities of BGB-283 in Chinese subjects with local advanced or metastatic malignant solid tumor.
Phase:
Phase 1
Details
Lead Sponsor:
BeiGene